Company Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt.
Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp.
The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Country | United States |
| IPO Date | Feb 19, 2004 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 408 |
| CEO | Ryan Spencer |
Contact Details
Address: 2100 Powell Street EmeryVille, California United States | |
| Website | https://www.dynavax.com |
Stock Details
| Ticker Symbol | DVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001029142 |
| CUSIP Number | 268158201 |
| ISIN Number | US2681582019 |
| Employer ID | 33-0728374 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan Spencer | Chief Executive Officer & Director |
| David F. Novack | President & Chief Operating Officer |
| Kelly MacDonald CPA | Senior Vice President & Chief Financial Officer |
| Donn Casale | Senior Vice President & Chief Commercial Officer |
| Dr. Dong Yu | Senior Vice President of Research |
| Dr. Robert Janssen M.D. | Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs |
| Jeff P. Coon | Senior Vice President & Chief Human Resources Officer |
| John L. Slebir | Senior Vice President & General Counsel |
| Justin Burgess | Chief Accounting Officer & Controller |
| Paul Cox | Vice President of Investor Relations & Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-A12B | Filing |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13D/A | [Amend] Filing |
| Oct 24, 2024 | 3 | Filing |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |